Detalles de la búsqueda
1.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Proc Natl Acad Sci U S A
; 115(43): E10119-E10126, 2018 10 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30297397
2.
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Oncologist
; 22(12): 1491-1499, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28798270
3.
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.
J Immunother Cancer
; 10(2)2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35190375
4.
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
J Thorac Oncol
; 17(2): 309-323, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34626838
5.
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
J Thorac Oncol
; 16(11): 1909-1924, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34311108
6.
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations.
Expert Rev Respir Med
; 14(2): 125-136, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31829747
7.
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
J Clin Oncol
; 38(22): 2530-2542, 2020 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32459597
8.
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Lancet Respir Med
; 7(5): 387-401, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30922878
9.
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Eur J Cancer
; 86: 186-196, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28992562
10.
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
J Clin Oncol
; 35(24): 2781-2789, 2017 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-28609226
11.
Lysophospholipid mediators of immunity and neoplasia.
Biochim Biophys Acta
; 1582(1-3): 161-7, 2002 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-12069824
12.
Lysophospholipid growth factors and their G protein-coupled receptors in immunity, coronary artery disease, and cancer.
ScientificWorldJournal
; 2: 324-38, 2002 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-12806020
13.
Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.
J Med Chem
; 55(3): 1368-81, 2012 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-22214363
14.
Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate.
J Immunol
; 169(8): 4084-7, 2002 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12370333
15.
Biochemical regulation of breast cancer cell expression of S1P2 (Edg-5) and S1P3 (Edg-3) G protein-coupled receptors for sphingosine 1-phosphate.
J Cell Biochem
; 88(4): 732-43, 2003 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12577307
Resultados
1 -
15
de 15
1
Próxima >
>>